ES2207858T3 - Composicion farmaceutica activa para reducir la produccion de proteina mcp-1". - Google Patents
Composicion farmaceutica activa para reducir la produccion de proteina mcp-1".Info
- Publication number
- ES2207858T3 ES2207858T3 ES98943862T ES98943862T ES2207858T3 ES 2207858 T3 ES2207858 T3 ES 2207858T3 ES 98943862 T ES98943862 T ES 98943862T ES 98943862 T ES98943862 T ES 98943862T ES 2207858 T3 ES2207858 T3 ES 2207858T3
- Authority
- ES
- Spain
- Prior art keywords
- mcp
- compound
- formula
- production
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 8
- 238000004519 manufacturing process Methods 0.000 title description 7
- 102100021943 C-C motif chemokine 2 Human genes 0.000 title 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 7
- 208000019693 Lung disease Diseases 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 239000007943 implant Substances 0.000 claims abstract description 5
- 210000000056 organ Anatomy 0.000 claims abstract description 5
- 208000035965 Postoperative Complications Diseases 0.000 claims abstract description 3
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 3
- 150000007530 organic bases Chemical class 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000013130 cardiovascular surgery Methods 0.000 abstract 1
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 description 12
- 229950009949 bindarit Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000036778 atheroma formation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001789A IT1293795B1 (it) | 1997-07-28 | 1997-07-28 | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| ITMI971789 | 1997-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2207858T3 true ES2207858T3 (es) | 2004-06-01 |
Family
ID=11377642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98943862T Expired - Lifetime ES2207858T3 (es) | 1997-07-28 | 1998-07-22 | Composicion farmaceutica activa para reducir la produccion de proteina mcp-1". |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6534534B1 (enExample) |
| EP (1) | EP1005332B1 (enExample) |
| JP (2) | JP4651191B2 (enExample) |
| AR (1) | AR016382A1 (enExample) |
| AT (1) | ATE251902T1 (enExample) |
| AU (1) | AU744492B2 (enExample) |
| CA (1) | CA2300289C (enExample) |
| DE (1) | DE69819012T2 (enExample) |
| DK (1) | DK1005332T3 (enExample) |
| ES (1) | ES2207858T3 (enExample) |
| IT (1) | IT1293795B1 (enExample) |
| PT (1) | PT1005332E (enExample) |
| SI (1) | SI1005332T1 (enExample) |
| WO (1) | WO1999004770A2 (enExample) |
| ZA (1) | ZA986636B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| LT2254869T (lt) | 2008-03-07 | 2017-08-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška |
| CA2714436C (en) | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| JP5509102B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用 |
| PL2462119T3 (pl) | 2009-08-03 | 2014-10-31 | Acraf | Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich |
| UA108742C2 (uk) * | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| US9250253B2 (en) | 2010-02-25 | 2016-02-02 | Prairie Ventures, L.L.C. | System and method for anatomical pathology sample handling, storage, and analysis |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| EP3142664B1 (en) * | 2014-05-15 | 2019-12-04 | Translatum Medicus Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| WO2016201426A1 (en) | 2015-06-12 | 2016-12-15 | Vettore, LLC | Mct4 inhibitors for treating disease |
| IL279949B2 (en) | 2016-12-12 | 2025-03-01 | Vettore Llc | Heterocyclic MCT4 inhibitors |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| IT1253703B (it) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| WO1994009128A1 (en) * | 1992-10-22 | 1994-04-28 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting vascular restenosis |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| JPH08333262A (ja) * | 1995-04-07 | 1996-12-17 | Chugai Pharmaceut Co Ltd | 免疫抑制剤 |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE19538402A1 (de) * | 1995-10-14 | 1997-04-17 | Boehringer Mannheim Gmbh | Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel |
| JPH09165339A (ja) * | 1995-10-27 | 1997-06-24 | American Home Prod Corp | ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長 |
| IT1276031B1 (it) * | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
-
1997
- 1997-07-28 IT IT97MI001789A patent/IT1293795B1/it active IP Right Grant
-
1998
- 1998-07-22 WO PCT/EP1998/004924 patent/WO1999004770A2/en not_active Ceased
- 1998-07-22 ES ES98943862T patent/ES2207858T3/es not_active Expired - Lifetime
- 1998-07-22 DK DK98943862T patent/DK1005332T3/da active
- 1998-07-22 EP EP98943862A patent/EP1005332B1/en not_active Expired - Lifetime
- 1998-07-22 US US09/463,666 patent/US6534534B1/en not_active Expired - Lifetime
- 1998-07-22 DE DE69819012T patent/DE69819012T2/de not_active Expired - Lifetime
- 1998-07-22 AU AU91601/98A patent/AU744492B2/en not_active Ceased
- 1998-07-22 SI SI9830573T patent/SI1005332T1/xx unknown
- 1998-07-22 CA CA002300289A patent/CA2300289C/en not_active Expired - Fee Related
- 1998-07-22 AT AT98943862T patent/ATE251902T1/de active
- 1998-07-22 JP JP2000503829A patent/JP4651191B2/ja not_active Expired - Fee Related
- 1998-07-22 PT PT98943862T patent/PT1005332E/pt unknown
- 1998-07-24 ZA ZA986636A patent/ZA986636B/xx unknown
- 1998-07-28 AR ARP980103695A patent/AR016382A1/es unknown
-
2009
- 2009-11-09 JP JP2009270715A patent/JP5086322B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IT1293795B1 (it) | 1999-03-10 |
| CA2300289A1 (en) | 1999-02-04 |
| JP2010047609A (ja) | 2010-03-04 |
| HK1028561A1 (en) | 2001-02-23 |
| SI1005332T1 (en) | 2004-02-29 |
| US6534534B1 (en) | 2003-03-18 |
| DE69819012D1 (de) | 2003-11-20 |
| JP5086322B2 (ja) | 2012-11-28 |
| DK1005332T3 (da) | 2004-02-09 |
| AR016382A1 (es) | 2001-07-04 |
| WO1999004770A3 (en) | 1999-04-15 |
| ZA986636B (en) | 1999-02-04 |
| AU744492B2 (en) | 2002-02-28 |
| JP4651191B2 (ja) | 2011-03-16 |
| AU9160198A (en) | 1999-02-16 |
| JP2001510793A (ja) | 2001-08-07 |
| CA2300289C (en) | 2007-11-20 |
| WO1999004770A2 (en) | 1999-02-04 |
| ITMI971789A1 (it) | 1999-01-28 |
| PT1005332E (pt) | 2004-03-31 |
| EP1005332A2 (en) | 2000-06-07 |
| DE69819012T2 (de) | 2004-08-12 |
| ATE251902T1 (de) | 2003-11-15 |
| EP1005332B1 (en) | 2003-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5086322B2 (ja) | Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物 | |
| TWI259077B (en) | Combinations of drugs for the treatment of neoplastic disorders | |
| US10434142B2 (en) | Compositions and methods of improved wound healing | |
| JPH04500070A (ja) | アスピリンの新規投与方法およびアスピリンを含有する新規剤形 | |
| KR100424503B1 (ko) | 암전이억제제 | |
| JPH11500119A (ja) | インターロイキン１２を用いる脈管形成の阻害 | |
| EA010650B1 (ru) | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек | |
| CN116350746A (zh) | 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用 | |
| JP7612025B2 (ja) | 敗血症を治療するための薬物組成物及びその使用 | |
| CN111346081A (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| US6191158B1 (en) | Pharmaceutical composition active in reducing production of MCP-1 protein | |
| JP3587851B2 (ja) | Ｔｎｆ誘発病状の治療におけるベンジダミンの使用 | |
| EP1203585B1 (en) | Anti-ischemic agent | |
| HK1028561B (en) | Pharmaceutical composition for reducing production of mcp-1 protein | |
| JP3851668B2 (ja) | 医薬用組成物 | |
| CZ2000292A3 (cs) | Farmaceutický prostředek aktivní při snižování produkce proteinu MCP-1 | |
| ES2367802T3 (es) | Medicamento capaz de inhibir la activación del factor de transcripción klf5. | |
| MXPA00001003A (en) | A pharmaceutical composition active in reducing production of mcp-1 protein | |
| CN118490681A (zh) | 瑞香素在制备治疗淋巴回流障碍的药物中的应用 | |
| CN108042525B (zh) | 一种治疗心肌梗死后心室重塑的药物组合物 | |
| CN118512430A (zh) | 一种盐酸米多君在减轻肠缺血再灌注损伤药物中的应用 | |
| TWI373338B (en) | Pharmaceutical composition containing transcription factor decoys and their preparation method and applications | |
| ES2548090T3 (es) | Uso de una suspensión oral que comprende acetato de megestrol para el tratamiento de asma bronquial | |
| ES2379829T3 (es) | Cicatrización de heridas y úlceras mediada por isoniazida | |
| TWI222362B (en) | Use of chitinous materials for inhibiting cellular nitric oxide production |